Company ProfilePremium

Alpa Laboratories Limited

Company Profile Analysis

Tickers: ALPA.NS, 532878.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Alpa Laboratories Limited - Company showcase

Year Founded & Workforce

1967

410 Employees

Alpa Laboratories Limited logo

Alpa Laboratories Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Alpa Laboratories Limited Overview

Alpa Laboratories is a micro-cap, promoter-controlled Indian manufacturer of pharmaceutical finished dosage forms (FDFs) operating from a single WHO-GMP and ISO 9001-certified multi-dosage plant at Rau, near Indore. It produces injectables (liquid and dry-powder vials and ampoules), tablets, capsules, eye and ear drops, ointments, creams and gels for human use, and boluses, injections and intra-mammary infusions for veterinary use. It earns revenue through four channels: its own "Alpa" branded generics, a veterinary division, exports to emerging markets across Africa, Asia, Latin America and the CIS, and third-party contract manufacturing for domestic majors such as Cipla, Zydus, Lupin and Glenmark. With FY2026 revenue of about INR 106 Cr, virtually no debt and a treasury book of roughly INR 138 Cr that exceeds its market value, the company is better characterised as a cash-rich holding wrapped around a low-margin, sub-scale formulations business whose operating profitability has deteriorated sharply since FY2022.


Company's own description

Across its annual reports and exchange profile, the company describes itself as a WHO-GMP and ISO 9001:2000 certified company that manufactures a wide range of pharmaceutical finished dosage forms under its own brand and for other Indian and multinational companies, with a product range spanning ethical, generic and over-the-counter (OTC) drugs for both human and veterinary use (Screener key points citing alpalabs.in; CRISIL rating rationale, August 2025). For financial reporting, the company treats its entire operation as a single business segment, "Drugs and Chemicals" (FY2023 annual report, as cited by Screener).

What the company does

Alpa manufactures generic formulations in most conventional dosage forms at its Rau facility, which began commercial production in 1999 and has dedicated areas for liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels (IIFL company summary; MarketsMojo company CV). Its therapeutic coverage, as summarised in investor-database descriptions derived from company materials, includes anti-infectives (antibacterials, antibiotics, antifungals, antiprotozoals, antivirals), analgesics and anti-inflammatories, cough and cold, cardiovascular, anti-diabetic, nutritional supplements, psychotropics, skin care, and ear and eye care (Investing.com profile).

Business model and revenue model

DivisionRevenue modelCustomer type
Branded Generic DivisionSale of own-brand products under the "Alpa" trademark through distributors, retail chemists, pharmacies and hospitalsDistributors, stockists, hospitals, retail pharmacies (India)
Veterinary DivisionSale of animal-health formulations (boluses, injections, intra-mammary infusions)Veterinary distributors, dairy/livestock channel
Exports DivisionSale of formulations to importers and distributors in emerging markets, either under Alpa brands or partner brandsOverseas distributors, government/tender buyers (detail not disclosed)
Contract Manufacturing DivisionLoan-licence / third-party manufacturing for other pharma companies' brandsIndian pharma companies including Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt

The business is almost entirely product-based manufacturing revenue. There is no subscription or licensing revenue disclosed. Within product revenue, management historically organised marketing into four divisions (IIFL company summary):

Division-level revenue split: not publicly disclosed in sources accessed.

A material point for analysts: the "Alpa" trademark under which branded products are sold is registered in the name of Alpa Labs (India) Limited, a promoter-group company, not the listed entity (IIFL company summary). The listed company therefore does not own its principal brand asset, creating related-party dependency.

Value-chain position

Alpa sits in the downstream formulation stage: it buys active pharmaceutical ingredients (APIs) and excipients, converts them into finished dosage forms, and sells either into its own distribution channel or to brand owners. It does not manufacture APIs and is not known to conduct original drug discovery. Its economic position is that of a price-taker in commoditised generic molecules (penicillins, albendazole, paracetamol, tinidazole, etc.) where competition is intense and margins are thin.

Independent characterisation

The financial statements tell a story that differs materially from the "pharma manufacturer" label. In FY2025, other income (largely gains on investments) of INR 23.35 Cr was nearly five times operating EBITDA of INR 4.75 Cr (Anand Rathi, FY2025). In FY2026, other income of INR 15.76 Cr compared with operating EBITDA of INR 3.29 Cr. Consolidated investments and short-term securities rose from INR 70.3 Cr (FY2022) to INR 137.9 Cr (FY2026) (StockAnalysis balance sheet). The company has paid no dividend in at least a decade (Finanzen dividend calendar). In effect, the operating business generates modest cash that is accumulated in a growing treasury portfolio, and reported earnings are driven mainly by that portfolio's returns. In Q1 FY2027 (June 2026 quarter), the operating line turned negative (operating loss of INR 3.96 Cr), with other income of INR 5.77 Cr keeping the company profitable (Screener quarterly).

End-markets served

India domestic generics (branded and trade generics); Indian animal health; emerging-market exports (Philippines, Iran, Iraq, Sierra Leone, Madagascar, Kenya, Liberia, Puerto Rico, Haiti, Sudan, Ghana, Nigeria, Sri Lanka per IIFL; also South and Central America, Africa, Asia and CIS countries including Russia, Ukraine and Kazakhstan per Investing.com and Stoxray profiles); and B2B contract manufacturing for Indian pharma majors.

Strategy

Stated strategy

The company does not hold earnings calls, publish investor presentations or host investor days, and no formal medium-term strategy document was found. The FY2025 annual report's Management Discussion & Analysis is largely an industry overview: it frames the global pharma market at USD 1.65 trillion in 2024, growing towards approx. USD 2.35 trillion by 2030, and notes India's pharma exports exceeded USD 30.47 billion in FY2025, up 9% year on year (IIFL reproduction of FY2025 MD&A). Company-specific themes in the FY2025 Directors' Report focus on human-resources practices: competitive compensation benchmarked against peer pharma companies, medical insurance, incentive programmes, long-service awards and employee engagement (IIFL Directors' Report FY2025).

Initiatives in the last 24 months

InitiativeDateDetailStatus
Fixed-asset investmentFY2025INR 11.4 Cr capex, nearly doubling net PPE; purpose not disclosedCompleted (FY2026 capex fell to INR 4.0 Cr)
"Acquisition" disclosure under Reg. 30Feb 2025Announcement categorised as acquisition; target/value not disclosed in sources accessed—
Board strengtheningFeb 2025Executive redesignation of Vitthal KothanaCompleted
INR 160 Cr loan/investment authority30 Sep 2026Shareholders approved authority (likely under Section 186/180 of the Companies Act) of up to INR 160 Cr, which is more than the company's market cap and close to total equityApproved; deployment not announced
Norfolk Mercantile mergerSince Dec 2017Simplification of group structurePending at NCLT

Sustainability/ESG commitments, cost programmes with targets and medium-term financial guidance: not publicly disclosed.

Implied strategy (analyst view)

Observed behaviour suggests a conservative, promoter-run strategy: maintain the formulation and contract-manufacturing business at roughly INR 100 to 115 Cr revenue, avoid leverage, and accumulate surplus cash in financial investments rather than distribute it or redeploy it in growth capex. The INR 160 Cr authority approved in September 2026 is the most significant signal of a possible change in capital deployment, but its purpose (inter-corporate loans, investments, guarantees or a strategic transaction) has not been disclosed.

Products & Services

The company does not publish revenue by product, product launch years or pricing. The catalogue below is compiled from product descriptions in investor databases that reproduce the company's product listings (Wright Research; Zonebourse; Investing.com; Stoxray). All products are generic molecules sold in pharmacopoeial grades (IP = Indian Pharmacopoeia; BP = British; USP = United States). Pricing is subject to India's Drug Price Control Order for scheduled molecules; company-specific pricing is not publicly disclosed.

Human health — capsules

ProductDescription / useTarget customerNotes
Ampicillin Capsules IP/BPBroad-spectrum penicillin antibioticDomestic trade, export tendersCommodity anti-infective
Amoxycillin Trihydrate Capsules IP/BPAminopenicillin antibiotic, most widely used oral antibioticDomestic trade, exportsHigh-volume, price-competitive
Cloxacillin Capsules IP/BPPenicillinase-resistant penicillin for staphylococcal infectionsExports, hospitals—
Piroxicam Capsules IP/BPNSAID for arthritis/painDomestic trade, exports—

Human health — creams, gels, ointments

ProductDescription / useTarget customer
Lidocaine Hydrochloride Jelly IP/USPTopical local anaesthetic (catheterisation, minor procedures)Hospitals, exports
Nitrofurazone Cream USPTopical antibacterial for burns and woundsHospitals, exports
Miconazole Cream IP/BPTopical azole antifungalRetail, exports
Clobetasol Ointment/Cream BPSuper-potent topical corticosteroidRetail, exports

Human health — injectables (liquid and dry powder)

ProductDescription / useTarget customer
Benzylpenicillin Injection IP/BPParenteral penicillin GHospitals, government/export tenders
Benzathine Penicillin Injection IP/BPLong-acting penicillin (syphilis, rheumatic fever prophylaxis)Public-health tenders, exports
Other liquid and dry-powder vials and ampoulesFacility capability for both formsContract-manufacturing clients

Note: one database lists the two penicillin injections under "ear and eye drops", which appears to be a transcription error; they are classified here as injectables.

Human health — tablets

ProductDescription / useTarget customer
Albendazole Tablets IP/USPBroad-spectrum anthelmintic (deworming)Exports to Africa/Asia, public-health programmes
Paracetamol Tablets IP/BPAnalgesic/antipyreticDomestic trade, exports
Tinidazole Tablets IP/BPAntiprotozoal/antibacterial (amoebiasis, giardiasis)Domestic trade, exports

Human health — eye and ear drops

The Rau plant has a dedicated area for eye and ear drops (MarketsMojo company CV). Named SKUs are not publicly disclosed in sources accessed.

Veterinary portfolio

ProductFormUse
Alpamin BolusOral bolusMineral/vitamin supplementation for livestock (inferred from name and category; composition not disclosed)
Alpazole BolusOral bolusAnthelmintic (albendazole-class, inferred from name)
Atropine Injection B.Vet.CInjectionAntidote/anticholinergic, British Veterinary Codex grade
Intra-mammary infusionsInfusionBovine mastitis treatment

Services

Contract manufacturing: Third-party production of finished dosage forms across the plant's capabilities for Indian pharma companies (Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt, per IIFL). Contract terms, volumes and revenue share: not publicly disclosed.

Discontinued capability

Containment / high-potency oral solids: The Pithampur Unit-II facility (operational 2012) was dedicated to oral hormonal and high-potency formulations. PitchBook records a manufacturing unit of Alpa Laboratories as acquired by Ipca Laboratories on 1 October 2014. The company therefore appears to have exited this higher-value niche.

Financial Narrative

All figures consolidated. Primary data source per table is stated. Blank cells = not publicly disclosed or not computable.

Income statement

Sources: Revenue, operating EBITDA, other income, EBITDA incl. OI from Anand Rathi; gross profit, EBIT, D&A, interest, PBT, tax, net income from StockAnalysis (INR M converted to Cr); EPS from Screener/TipRanks; dividends from Finanzen. Note: TipRanks reports FY2024 EPS as INR 8.01 and Screener INR 7.98 (weighted share-count difference). TipRanks reports a much lower gross profit (INR 18.9 to 19.4 Cr for FY2024-25) using a different cost classification; StockAnalysis figures are used here.

Margins and growth

Derived from table 6.1. Revenue CAGR FY2022 to FY2026 (4 years): approx. -1.5%. Revenue CAGR FY2021 (INR 97.55 Cr) to FY2026 (5 years): approx. +1.6%. Screener reports 5-year compounded sales growth of 2% and 10-year of 7%.

Commentary. The defining trend is the divergence between operating and reported profitability. Gross margin has been broadly stable at 30 to 34%, indicating that raw-material conversion economics have not collapsed; the deterioration sits lower in the P&L. Operating expenses (SG&A plus other operating costs) rose from INR 27.2 Cr in FY2022 to INR 33.9 Cr in FY2025 before easing to INR 30.3 Cr in FY2026 (StockAnalysis), on a revenue base that has not grown. As a result, operating EBIT margin compressed from 8.0% to 1.1% in four years. Net margin, by contrast, rose to a peak of 17.3% in FY2025 because other income (mostly realised gains on the investment portfolio: INR 19.8 Cr in FY2025, INR 9.0 Cr in FY2024, INR 8.8 Cr in FY2022 per StockAnalysis) more than offset the operating decline. By FY2026, other income accounted for 94% of pre-tax profit. The low FY2026 effective tax rate (approx. 10%) also flattered net income; Screener flags the tax rate as "low". The FY2026 inflection is negative on both operating and treasury lines, and Q1 FY2027 showed an outright operating loss despite 25% revenue growth, implying adverse product mix, pricing pressure or cost overruns not explained in public disclosures.

Balance sheet

Sources: StockAnalysis balance sheet (INR M converted); equity and borrowings from Screener (rounded to whole crore). Short-term debt derived as total borrowings minus long-term debt. Net debt derived as total borrowings minus cash and short-term investments. Book value per share derived from equity over 2.104 Cr shares; Screener reports INR 88.5 for FY2026.

Working capital (derived). Current liabilities are not separately reported in sources accessed. Using Screener's "other liabilities" plus borrowings as an upper-bound proxy for current liabilities gives approximate working capital of INR 104 Cr (FY2022), INR 117 Cr (FY2023), INR 131 Cr (FY2024), INR 141 Cr (FY2025) and INR 155 Cr (FY2026). The bulk of this is the treasury portfolio rather than operating working capital.

Commentary. The balance sheet has strengthened steadily: equity grew 52% from INR 122 Cr to INR 186 Cr in four years entirely through retained earnings, since no dividends were paid and no shares issued. The treasury portfolio nearly doubled. Operating assets remain modest; net PPE stepped up from INR 11.4 Cr to INR 20.6 Cr in FY2025 following INR 11.4 Cr of capex (the purpose of which is not disclosed in sources accessed). Goodwill is negligible. Receivables are high relative to sales (debtor days 141 in FY2026), a long-standing feature consistent with contract-manufacturing and export credit terms.

Cash flow

Source: StockAnalysis cash flow statement (INR M converted). Screener's rounded figures (CFO INR 10, 9, 4, 18, 9 Cr; FCF INR 8, 8, -3, 7, 6 Cr) are consistent.

Commentary. Operating cash flow is volatile and heavily influenced by working-capital swings. The FY2025 spike to INR 18.3 Cr was driven by a INR 20.4 Cr increase in payables, i.e. stretching suppliers, rather than by underlying profitability (operating EBITDA was only INR 4.75 Cr that year). Cumulative five-year FCF of approx. INR 25.7 Cr compares with cumulative reported net income of INR 78 Cr; the gap reflects that most reported profit is non-cash or investment-related gains that are recycled within the portfolio. None of the cash generated has been returned to shareholders.

Ratios

Sources: ROCE, debtor/inventory/payable days and CCC from Screener ratios. ROE, ROA, D/E, net debt/EBITDA, interest coverage and asset turnover derived from tables 6.1 and 6.3 using average balances (FY2021 equity INR 108 Cr and total assets INR 140 Cr from Screener). Operating ROIC derived as EBIT excl. OI divided by (equity + borrowings - cash & short-term investments), averaged; this isolates the operating business. Screener reports FY2026 ROE as 8.38%; MarketInOut reports a ROIC of -1.58% on a TTM basis.

Commentary. Headline ROE of 8 to 12% conceals two very different businesses. The operating business's pre-tax return on the capital actually deployed in it has fallen from approx. 13% to approx. 1%, which is below any reasonable cost of capital. The treasury portfolio, which represents more than half of total assets, is earning the remainder. Asset turnover has halved partly because idle treasury assets swell the denominator. Interest coverage has declined sharply but debt is trivial, so solvency risk is negligible. The CRISIL B rating reflects information non-cooperation rather than financial stress.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipStatus

Alpa Laboratories Limited

Listed parent

Operating company

Norfolk Mercantile Private Limited

100% subsidiary (acquired FY2014-15)

Merger into parent pending before NCLT Mumbai since 7 Dec 2017

Alpa Labs (India) Limited

Promoter-group company (not a subsidiary)

Registered owner of "Alpa" trademark

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2022FY2023FY2024FY2025FY2026

Segment revenue Drugs and Chemicals (INR Cr)

112.2792.44108.74112.45105.81

Segment operating EBITDA excl. other income (INR Cr)

10.697.568.114.753.29

Segment EBITDA margin (%)

9.58.27.54.23.1

YoY revenue growth (%)

15.1-17.717.63.4-5.9

Contribution to total revenue (%)

100100100100100

Revenue History

QuarterSalesOperating profitOPM %Other incomePBTNet profit

Jun 2024 (Q1 FY25)

21.440.532.55.165.105.10

Sep 2024 (Q2 FY25)

24.943.3213.36.919.657.69

Dec 2024 (Q3 FY25)

26.150.742.88.808.908.90

Mar 2025 (Q4 FY25)

39.920.200.52.482.08-2.12

Jun 2025 (Q1 FY26)

19.110.432.311.9411.7711.77

Sep 2025 (Q2 FY26)

26.26-2.25-8.63.060.110.11

Dec 2025 (Q3 FY26)

29.051.515.20.911.741.59

Mar 2026 (Q4 FY26)

31.403.6011.5-0.163.071.38

Jun 2026 (Q1 FY27)

23.93-3.96-16.65.770.980.98

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

112.2792.44108.74112.45105.81

Gross profit (INR Cr)

36.1631.2934.1436.4131.51

Operating EBITDA excl. other income (INR Cr)

10.697.568.114.753.29

Other income (INR Cr)

10.789.9314.8923.3515.76

EBITDA incl. other income (INR Cr)

21.4617.4923.0028.1019.05

Depreciation & amortisation (INR Cr)

1.661.331.962.202.09

Operating income EBIT excl. other income (INR Cr)

9.016.766.662.501.20

Interest expense (INR Cr)

0.110.080.360.230.26

Pre-tax income (INR Cr)

19.5615.8920.6825.6716.70

Income tax (INR Cr)

5.473.313.916.161.69

Net income (INR Cr)

14.0912.5816.7819.5015.01

EPS basic (INR)

6.705.987.989.277.13

EPS diluted (INR)

6.705.987.989.277.13

Dividend per share (INR)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

32.233.731.432.429.8

Operating EBITDA margin excl. OI (%)

9.58.27.54.23.1

Operating EBIT margin (%)

8.07.36.12.21.1

Net margin (%)

12.513.615.417.314.2

Other income as % of PBT

55.162.572.091.094.4

Revenue growth YoY (%)

15.1-17.717.63.4-5.9

Net income growth YoY (%)

94.4-10.733.416.2-23.0

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

155.2167.3182.4222.6242.1

Cash & equivalents (INR Cr)

1.588.811.712.222.84

Cash + short-term investments/trading securities (INR Cr)

70.2780.8492.85112.70137.90

Long-term investments (INR Cr)

7.477.778.278.776.62

Accounts receivable (INR Cr)

38.0446.7341.1546.8340.83

Inventory (INR Cr)

15.4612.6413.6717.6413.33

Net property, plant & equipment (INR Cr)

9.226.9611.4120.6020.12

Goodwill & intangibles (INR Cr)

0.100.080.060.050.04

Total current assets (INR Cr)

138.0149.1161.0192.5210.9

Accounts payable (INR Cr)

14.9215.0611.7818.6917.79

Total borrowings (INR Cr)

62503

Long-term debt (INR Cr)

2.130.78000

Short-term debt (INR Cr, derived)

3.871.22503

Net debt (INR Cr; negative = net cash)

-64.3-78.8-87.9-112.7-134.9

Shareholders' equity (INR Cr)

122135152172186

Book value per share (INR)

58.064.272.281.788.4

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

9.948.903.6518.329.95

Capital expenditure (INR Cr)

-2.19-1.13-6.39-11.38-3.95

Free cash flow (INR Cr)

7.757.77-2.746.946.00

Net purchase of investment securities (INR Cr)

-19.18-0.03-9.51-3.39-10.35

Dividends paid (INR Cr)

00000

Share buybacks (INR Cr)

00000

Change in receivables (INR Cr)

7.59-6.645.25-7.595.60

Change in payables (INR Cr)

-8.201.98-3.7120.40-0.90

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%)

12.69.811.712.08.4

ROA (%)

9.57.89.69.66.4

ROCE (%)

91215169

Operating ROIC excl. treasury, pre-tax (%)

13.19.38.32.71.3

Current ratio (x, derived proxy)

4.14.75.43.83.8

Debt / equity (x)

0.050.010.030.000.02

Net debt / EBITDA incl. OI (x)

-3.0-4.5-3.8-4.0-7.1

Interest coverage EBIT excl. OI / interest (x)

848119115

Asset turnover (x)

0.760.580.620.560.45

Debtor days

124184138155141

Inventory days

8184739273

Payable days

78100639798

Cash conversion cycle (days)

127168149150116

Revenue by Region

RegionFY2024FY2025FY2026

Total revenue (INR Cr)

108.74112.45105.81

Valuation Snapshot

MetricValueSource

Last price (1 Oct 2026)

INR 59.3

Screener

52-week high / low

INR 99.8 / INR 46.0

Screener

1-year return

-33%

Screener

3-year CAGR

-8%

Screener

5-year CAGR

+1%

Screener

10-year CAGR

+6%

Screener

All-time reference

5-year low INR 11.20 and 5-year high INR 144.50 (as of Mar 2025)

Equentis

Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

EPS (INR)

6.705.987.989.277.13

Book value per share (INR)

58.064.272.281.788.4

Dividend per share (INR)

00000

Valuation Multiples

MultipleAlpaBasis

P/E (TTM)

30.7x

Screener (TTM EPS INR 1.94)

P/E (FY2026)

8.3x

INR 59.3 / FY2026 EPS INR 7.13 (derived)

P/B

0.67x

Screener

EV/Sales

approx. -0.1x

EV approx. INR -10 Cr (market cap INR 125 Cr + debt INR 3 Cr - cash/ST investments INR 137.9 Cr) (derived)

Credit Ratings

AgencyFacilityAmount (INR Cr)RatingOutlookDate

CRISIL

Cash credit (long term)

14

CRISIL B (Issuer Not Cooperating)

Stable

29 Aug 2025

CRISIL

Bank guarantee (short term)

1

CRISIL A4 (Issuer Not Cooperating)

—

29 Aug 2025

CRISIL

Letter of credit (short term)

1

CRISIL A4 (Issuer Not Cooperating)

—

29 Aug 2025

Moody's / S&P / Fitch

——

Not rated

——

Analyst Conclusions

Management guidance

None. The company provides no financial guidance, holds no earnings calls and publishes no investor presentations.

Consensus expectations

No consensus estimates exist.

Bull case

  1. Asset backing exceeds price. Liquid investments of INR 137.9 Cr (FY2026) exceed market cap of approx. INR 125 Cr, and total book equity of INR 186 Cr implies a 33% discount. Investors effectively receive the operating business, plant and INR 20 Cr of PPE for free.

  2. Operating recovery potential. Q1 FY2027 revenue grew 25.2% YoY; with gross margins still at approx. 30% and newly expanded capacity (FY2025 capex INR 11.4 Cr), restoring opex discipline to FY2022 levels could return operating EBITDA to INR 10 Cr or more.

  3. Catalyst optionality. The INR 160 Cr authority, a long-overdue Norfolk merger completion, or a first-ever dividend could unlock the treasury discount.

Bear case

  1. Operating business is value-destructive. Operating ROIC fell to approx. 1% in FY2026 and turned negative in Q1 FY2027, with no disclosed plan to fix it.

  2. Cash may never reach minorities. No dividend in a decade, a promoter-owned brand, CRISIL non-cooperation and frequent compliance-officer turnover suggest the treasury discount is rational, and the new INR 160 Cr authority raises the risk of related-party or non-core deployment.

  3. Earnings are market-dependent. With 90%+ of PBT from investment income, reported EPS could fall sharply in a weak equity or debt market, and TTM P/E is already 30.7x.

Catalysts and monitorables (next 12 months)

  • Q2 FY2027 results (expected around 12 November 2026): whether operating losses persist after the Q1 FY2027 loss.

  • Disclosure of the purpose of the INR 160 Cr loan/investment authority and any inter-corporate loans or investments made under it.

  • Composition of the treasury portfolio (equity versus debt funds) and realised gains.

  • Any dividend or buyback announcement.

  • Norfolk Mercantile NCLT outcome.

  • Stability of the company secretary/compliance function.

  • Promoter shareholding changes (57.19% at June 2026).

  • CRISIL rating review (typically around August).

Analyst verdict

Alpa Laboratories is not, in substance, the pharmaceutical growth story its sector label implies. It is a micro-cap holding company in which a single-site generic formulations plant generating roughly INR 100 to 115 Cr of revenue is attached to a liquid investment portfolio that has grown to about INR 138 Cr, larger than the company's entire market value. The operating franchise has eroded steadily: operating EBITDA margin fell from 9.5% in FY2022 to 3.1% in FY2026, and the June 2026 quarter produced an operating loss of nearly INR 4 Cr even as revenue rose by a quarter. Reported profits and headline ROE have been sustained almost entirely by investment income, which accounted for more than 90% of pre-tax profit in each of the last two fiscal years.

The stock's discount to book (0.67x) and to its own cash pile is therefore not an obvious mispricing. It reflects a decade without a dividend, a primary trademark owned by a promoter-group entity, a credit-rating relationship classified as non-cooperative for four years running, an intra-group merger stalled at the NCLT since 2017, and rapid turnover of compliance officers. The September 2026 shareholder approval of an INR 160 Cr loan and investment authority, exceeding the company's market capitalisation, is the pivotal open question: deployed into an accretive acquisition or returned to shareholders, it could close the discount; deployed into related or non-core assets, it would confirm the market's scepticism.

On balance, the evidence supports a cautious stance. The downside is cushioned by hard asset backing and a debt-free balance sheet, so permanent capital loss risk appears limited at current prices, but there is no visible catalyst for re-rating within management's demonstrated behaviour. Investors should treat the shares as a deep-value, governance-dependent special situation, and should require concrete evidence of capital return or an operating turnaround, most immediately in the November 2026 results and in the use of the new borrowing authority, before taking a constructive view.


Principal sources: NSE/BSE exchange filings (results for quarters ended Sep 2025 and Dec 2025; AGM outcomes; Reg. 30 disclosures); Alpa Laboratories annual reports FY2022, FY2024 and FY2025 (via BSE and IIFL); CRISIL rating rationale, 29 Aug 2025; Screener.in consolidated financials and shareholding (accessed Oct 2026); StockAnalysis (income statement, balance sheet, cash flow FY2022-FY2026); Anand Rathi financial results; Kotak Neo quarterly results; TipRanks; IIFL/IndiaInfoline company summary; MarketsMojo company CV; MarketScreener event log; PitchBook; Fyers peer data; Finanzen dividend calendar; Morningstar; Investing.com; Univest (Q1 FY2027).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleCategoryTenure / notesSource

Mahendra Singh Chawla

Chairman

Promoter, director

Chairman in FY2022 and FY2024 annual reports; signs AGM notices

BSE annual reports FY2022, FY2024; Nirmal Bang

Paresh Chawla

Managing Director

Promoter, executive (DIN 00520411)

MD; reappointment approved at 38th AGM, 30 Sep 2026; largest individual shareholder at 34.26%

MarketsMojo; Screener announcements; FY2022 AR

Pravin Shah

Director

Promoter-group/non-independent (Shah family of founding partners, inferred)

Board member in FY2022 and FY2024 ARs

BSE ARs

Shitul Shah

Director

Non-independent

Board member per FY2024 AR

BSE AR FY2024

Vitthal Kothana

Executive Director / Whole-time Director

Executive

Appointed director c. 2022 (FY2022 AGM resolution); redesignated executive director 14 Feb 2025

FY2022 AR; MarketScreener

Sanket Baheti

Independent Director

Independent

Per FY2024 AR

BSE AR FY2024

Pratibha Lunawat

Independent Director

Independent

Per FY2024 AR

BSE AR FY2024

Jyoti Jain

Independent Director

Independent

Listed in both FY2022 and FY2024 ARs

BSE ARs

Devendra Baheti

Independent Director (former)

Independent

Listed in FY2022 AR; not in FY2024 AR

BSE AR FY2022

Additional / new independent director

Independent

Independent

An independent director appointment was approved at the 30 Sep 2026 AGM; name not confirmed in sources accessed

Screener announcements

Diksha Jaswani

Company Secretary & Compliance Officer

KMP

Appointed 17 Sep 2026

Screener announcements

Chief Financial Officer

KMP

—

Name not publicly disclosed in sources accessed

—

Board & Management Changes

DateEventSource

10 Dec 2024

Swati Bagh resigns as Company Secretary & Compliance Officer (announced 14 Nov 2024)

MarketScreener

13 Feb 2025

Srashti Chopra appointed Company Secretary & Compliance Officer

MarketScreener

14 Feb 2025

Vitthal Kothana redesignated non-executive to executive director

MarketScreener

25 Mar 2026

Srashti Chopra resigns

MarketScreener

11 Apr 2026

Yashoda Patidar appointed Company Secretary & Compliance Officer

Screener

26 Jul 2026

Yashoda Patidar resigns

MarketScreener

17 Sep 2026

Diksha Jaswani appointed Company Secretary & Compliance Officer

Screener

30 Sep 2026

MD reappointment and independent director appointment approved at AGM

Screener

Shareholding Trend

Holder categorySep 2025 (%)Dec 2025 (%)Mar 2026 (%)Jun 2026 (%)

Promoters

57.2957.2957.1957.19

Foreign institutional investors

0.350.360.380.35

Domestic institutional investors

0.000.000.000.07

Public

42.3642.3542.4342.38

Number of shareholders

18,54218,23617,90017,643

Competitive Landscape

Competitors by Segment

ActivityNamed competitorsPositioning versus Alpa

Contract / third-party FDF manufacturing

Akums Drugs & Pharmaceuticals; Synokem Pharmaceuticals (private); Innova Captab; Medicamen Biotech

Much larger scale and broader dosage portfolios; Alpa is a niche, single-site supplier

Branded/trade generics (India)

Lincoln Pharmaceuticals; Bal Pharma; Kopran; Brooks Laboratories

Similar small-cap profile; most have larger domestic field forces

Emerging-market exports

Lincoln Pharmaceuticals; Kopran; Marksans Pharma; Medicamen Biotech

Peers have regulated-market approvals or larger export books

Veterinary formulations

Zydus Animal Health (Zydus Lifesciences); Intas Animal Health (private); Hester Biosciences

Market dominated by larger specialist players

Indian pharma majors (also customers)

Sun Pharma; Cipla; Zydus Lifesciences; Lupin; Dr Reddy's; Aurobindo

Customers and competitors; incomparably larger

Peer Comparison FY2026

CompanyMarket cap (INR Cr)P/E (x)Annual PAT (INR Cr)

Sun Pharma

456,83337.811,479

Zydus Lifesciences

113,21725.15,040

Cipla

112,21233.33,879

Lupin

97,62617.75,333

Alpa Laboratories

13430.715

Company Snapshot

$12.2M

Revenue

410

Employees

1967

Founded

District Indore, India

Headquarters

SWOT Analysis

Strengths

  • Net-cash balance sheet: cash and short-term investments of INR 137.9 Cr versus borrowings of INR 3 Cr at 31 March 2026 (StockAnalysis; Screener).
  • Treasury value exceeds market cap: INR 137.9 Cr of liquid investments against market cap of approx. INR 125 Cr on 1 October 2026; stock trades at 0.67x book (Screener).
  • Sterile injectable capability: liquid and dry-powder injectables at Rau since 1999 (IIFL), a higher-barrier dosage form.
  • Blue-chip contract-manufacturing clients: Cipla, Zydus, Lupin, Glenmark among others (IIFL).
  • Consistent profitability: positive net income every year from FY2016 to FY2026 (Screener P&L).
  • Clean audit: unmodified audit opinion on FY2026 results (Screener announcement, 29 May 2026).

Weaknesses

  • Operating margin collapse: operating EBITDA margin down from 9.5% (FY2022) to 3.1% (FY2026); negative 16.6% in Q1 FY2027 (Anand Rathi; Screener).
  • Earnings quality: other income was 94% of FY2026 PBT and 91% of FY2025 PBT (derived from Anand Rathi).
  • Stagnant revenue: 5-year sales CAGR of approx. 1.6-2% (Screener; derived).
  • Brand not owned: "Alpa" trademark held by promoter-group Alpa Labs (India) Ltd (IIFL).
  • No dividends: zero payout for at least ten years despite retained cash (Finanzen; Screener).
  • Elevated receivables: debtor days 141-184 over FY2023-FY2026 (Screener ratios).

Opportunities

  • Capital redeployment: INR 160 Cr loan/investment authority approved 30 Sep 2026 could fund a value-accretive transaction (Screener announcement).
  • Revenue rebound: Q1 FY2027 revenue up 25.2% YoY (Screener).
  • Capacity added: FY2025 capex of INR 11.4 Cr nearly doubled net PPE, creating room for volume growth (StockAnalysis).
  • Export growth: Indian pharma exports grew 9% in FY2025 (FY2025 MD&A).
  • Group simplification: completing the Norfolk Mercantile merger pending since December 2017 (IIFL).
  • Capital return: with equity of INR 186 Cr and negligible debt, a dividend or buyback could re-rate the stock trading at 0.67x book (Screener).

Threats

  • Operating losses: Q2 FY2026 (INR -2.25 Cr) and Q1 FY2027 (INR -3.96 Cr) operating losses suggest structural cost or pricing pressure (Screener).
  • Market-linked earnings: realised investment gains swung from INR 3.3 Cr (FY2023) to INR 19.8 Cr (FY2025) (StockAnalysis); a market downturn could eliminate reported profit.
  • Governance perception: four company secretaries between Dec 2024 and Sep 2026 (MarketScreener; Screener) and CRISIL non-cooperation status since at least 2022 (CRISIL).
  • Capital-allocation risk: INR 160 Cr authority exceeds market cap; related-party deployment would be value-destructive for minorities.
  • Export-market risk: named markets include Iran, Sudan, Russia and Ukraine (IIFL; Investing.com).
  • Share-price momentum: 1-year return of -33% and 3-year CAGR of -8% (Screener), with 'Strong Sell' ratings from MarketsMojo's quant model.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
13 Feb 2025Q3 FY2025 results: consolidated net profit INR 8.89-8.90 Cr, up approx. 96% YoY Sharekhan; ScreenerStrong quarter driven by other income of INR 8.8 Cr; operating margin only 2.8%
13 Feb 2025Srashti Chopra appointed Company Secretary MarketScreenerFills vacancy after Swati Bagh's December 2024 exit
14 Feb 2025Vitthal Kothana redesignated executive director MarketScreenerBoard restructuring
Feb 2025Reg. 30 disclosure under "Acquisition" heading SharekhanDetails not available; monitor
17 Mar 2025Share price INR 102.6; market cap approx. INR 217 Cr EquentisPre-decline reference point
28 May 2025FY2025 results: record PAT INR 19.5 Cr; Q4 FY2025 loss of INR 2.12 Cr with tax rate above 200% MarketScreener; ScreenerPeak earnings year, but Q4 showed weakness
10 Jun 2025Share price INR 100.64; P/E 10.8; P/B 1.16 IIFL–
27 Jun 2025Annual secretarial compliance report for FY2025 filed, confirming compliance ScreenerRoutine
13-14 Aug 2025Q1 FY2026: revenue INR 19.1 Cr; PBT and PAT INR 11.77 Cr on other income of INR 11.94 Cr Screener; Kotak NeoEarnings almost wholly from treasury; operating revenue weakest in years
29 Aug 2025CRISIL reaffirms B/Stable / A4, issuer not cooperating; notes FY2025 revenue INR 111.65 Cr and PAT INR 19.68 CrFourth consecutive year of non-cooperation status
202537th Annual Report (FY2025) published; Norfolk Mercantile merger still pending at NCLT IIFL Directors' ReportSeven-plus years pending
22 Oct 2025Market cap INR 183 Cr; 1-year change -20.9% TipRanksDowntrend established
14 Nov 2025Q2 FY2026 results: net profit INR 0.11 Cr; operating loss INR 2.25 Cr Screener; NSE filingSharp earnings collapse
19 Dec 2025Share price INR 76.86; P/E 8.7; P/B 0.88 ICICI DirectStock moves below book value
11 Feb 2026Q3 FY2026: total income INR 29.96 Cr (-14.3% YoY); PAT INR 1.90 Cr (-78.7% YoY) Kotak Neo; NSE filingContinued weak profitability
17 Mar 2026Share price INR 59.76; 1-year return -40.7% Kotak NeoNear multi-year low territory
25 Mar 2026Company Secretary Srashti Chopra resigns MarketScreenerGovernance turnover
8 Apr 2026NSE seeks clarification on significant price movement Screener; MarketsMojoStock volatility (a 20% upper circuit episode is reported by MarketsMojo; exact date not confirmed)
9 Apr 2026Company clarifies there is no undisclosed price-sensitive event Screener–
11 Apr 2026Yashoda Patidar appointed Company Secretary Screener–
12 May 2026Board meeting intimation for FY2026 results ScreenerRoutine
29 May 2026FY2026 audited results approved with unmodified audit opinion; auditor appointments approved. Revenue INR 105.81 Cr (-5.9%); PAT INR 15.01 Cr (-23%) Screener; Anand RathiClean audit; second consecutive weak year operationally
Mar-Jun 2026Promoter holding reported at 57.19%, down from 57.29% ScreenerMarginal promoter selling or reclassification
26 Jul 2026Company Secretary Yashoda Patidar resigns MarketScreenerThird CS exit in 20 months
11 Aug (2026, year inferred)Clarification on board meeting date relative to earlier submission Nirmal BangMinor compliance correction
14 Aug 2026Q1 FY2027 results: revenue INR 23.93 Cr (+25.2% YoY); operating loss INR 3.96 Cr (OPM -16.6%); PAT INR 0.98 Cr Screener; UnivestRevenue recovery but deepest operating loss in the dataset
21 Aug 2026Share price INR 62.10; market cap INR 130.9 Cr InCred Money–
7 Sep 2026FY2026 Annual Report (Reg. 34) filed; book closure fixed for AGM Screener–
17 Sep 2026Diksha Jaswani appointed Company Secretary Screener–
30 Sep 202638th AGM: approves financials, MD reappointment, independent director, INR 160 Cr loan authority ScreenerLarge capital-deployment authority relative to company size
1 Oct 2026Share price INR 59.3; market cap INR 125 Cr; TTM P/E 30.7; P/B 0.67 ScreenerStock trades below treasury value
12 Nov 2026 (scheduled)Expected Q2 FY2027 results Finanzen calendarNext catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue from operations fell from INR 1,122.7 Mn in FY2022 to INR 1,058.1 Mn in FY2026.
Alpa Laboratories Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations1,122.7924.41,087.41,124.51,058.1
Gross profit361.6312.9341.4364.1315.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.